News
TCON
0.4298
+4.80%
0.0197
Weekly Report: what happened at TCON last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at TCON last week (0311-0315)?
Weekly Report · 03/18 09:44
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. Fell 14.7% to $42.42 on Thursday. The company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Aptorum Group Limited and Presto Automation were among the stocks moving in today's mid-day session. Build-A-Bear Workshop and DICK'S Sporting Goods were also among the gainers.
Benzinga · 03/14 17:38
12 Health Care Stocks Moving In Thursday's Intraday Session
Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. Aptorum Gr stock moved upwards by 43.65% to $6.22. Mira Pharmaceuticals stock rose by 17.27%.
Benzinga · 03/14 17:31
12 Health Care Stocks Moving In Wednesday's Intraday Session
Heron Therapeutics shares rose 35.4% to $3.19 during Wednesday's regular session. The company's, Q4 earnings came out yesterday. Trxade Health (NASDAQ:MEDS) shares fell 22.6% during the session. NuCana stock rose 34.32% and Cardiff Oncology shares increased by 27.9%.
Benzinga · 03/13 17:31
JonesTrading Reaffirms Their Hold Rating on TRACON Pharmaceuticals (TCON)
TipRanks · 03/13 12:46
12 Health Care Stocks Moving In Tuesday's Intraday Session
Regulus Therapeutics stock increased by 94.9% to $2.69 during Tuesday's regular session. Bright Green (NASDAQ:BGXX) shares increased by 66.42%. SCWorx and Assure Hldgs stock moved upwards by 29.33%. Lexaria Bioscience and NRX Pharmaceuticals were among the losers.
Benzinga · 03/12 17:31
Weekly Report: what happened at TCON last week (0304-0308)?
Weekly Report · 03/11 09:43
Buy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical Trials
TipRanks · 03/07 15:35
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NKGen Biotech shares increased by 69.4% to $1.46 during Wednesday's pre-market session. Creative Medical Tech (NASDAQ:CELZ) stock increased by 33.68% in the pre- market session. Aditxt stock rose 13.74% and Vincerx Pharma stock rose 19.34%.
Benzinga · 03/06 13:07
Tracon Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/06 11:47
Tracon Pharmaceuticals Price Target Cut to $6.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 03/06 11:47
HC Wainwright & Co. Maintains Buy on TRACON Pharma, Lowers Price Target to $6
Benzinga · 03/06 11:36
Press Release: TRACON Pharmaceuticals Reports -2-
Three months and year ended December 31, 2018 and 2017. The Company's net income for the three months ended December 30, 2018 was $3.2 million. The company's total revenue for the year was $27.9 million. The Company expects to report a net loss for the first quarter of 2018 and a profit for the second quarter.
Dow Jones · 03/05 21:02
Press Release: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
TRACON Pharmaceuticals, Inc. Reports fourth quarter and year-End 2023 financial results. The Company is on track to complete enrollment of 80 patients in the ongoing pivotal ENVASARC trial later this quarter. The company will host a conference call and webcast today at 4:30 PM.
Dow Jones · 03/05 21:02
Earnings Scheduled For March 5, 2024
Target is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion. Companies reporting before the bell include NIO, Target and Nordstrom. Companies expected to report earnings for their fourth quarter include Vivid Seats, V2X and NIO.
Benzinga · 03/05 10:00
Tracon Q4 2023 Earnings Preview
Seeking Alpha · 03/04 22:35
A Preview Of TRACON Pharma's Earnings
TRACON Pharma is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Analysts estimate the company will report an earnings per share of $-0.08. The company's shares are down 87.37% over the last 52-week period.
Benzinga · 03/04 18:03
Weekly Report: what happened at TCON last week (0226-0301)?
Weekly Report · 03/04 09:44
Weekly Report: what happened at TCON last week (0219-0223)?
Weekly Report · 02/26 09:48
More
Webull provides a variety of real-time TCON stock news. You can receive the latest news about Tracon Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About TCON
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.